Argenx reports half year 2021 financial results and provides second quarter business update

- completion of enrollment expected by year-end for adapt-sc and advance (iv) trials of efgartigimod; topline data for both trials expected in first half of 2022

ARGX Ratings Summary

ARGX Quant Ranking